Cell-free DNA is rapidly expanding beyond its established roles in oncology and prenatal screening, with increasing relevance for transfusion medicine and clinical laboratory practice, as described in a new article from the College of American Pathologists (CAP) authored by Pearl Audon, DO, FCAP, and Gagan Mathur, MD, MBA, CPE, FCAP.
Cell-free DNA (cfDNA) consists of short DNA fragments that circulate freely in the bloodstream, primarily released from apoptotic and necrotic cells. First identified in the 1940s and later advanced through the discovery of fetal cfDNA in maternal plasma in the 1990s, cfDNA continues to gain momentum as a transformative tool in laboratory medicine.
Although most cfDNA in healthy individuals originates from hematopoietic cells, it can also arise from fetal tissue, transplanted organs, pathogens, or malignant cells, supporting its utility as a minimally invasive biomarker across diverse clinical settings.
“Cell-free DNA gives pathologists new insight into what’s happening inside the body using a simple blood sample,” Mathur said in a press release. “As this technology continues to evolve, it has the potential to improve diagnostic accuracy, guide clinical decision-making, and ultimately enhance patient outcomes across multiple settings.”
Established applications gaining traction
The article emphasizes noninvasive fetal blood group genotyping as one of the most established uses of cfDNA in transfusion medicine. By analyzing maternal plasma, laboratories can determine fetal RhD status and other clinically significant antigens without the need for invasive procedures.
“This approach minimizes the need for invasive procedures like amniocentesis and reduces the risk of alloimmunization by allowing targeted management during pregnancy,” the authors noted.
This supports more precise administration of Rh immune globulin, reducing unnecessary use while improving patient safety and conserving healthcare resources.
In transplantation, donor-derived cfDNA is emerging as a valuable tool for monitoring graft health. Measuring donor-specific cfDNA in circulation allows for earlier detection of graft injury or rejection, enabling more timely clinical intervention and personalized patient management.
Emerging opportunities for laboratory medicine
Beyond these established applications, the authors outline a growing range of emerging uses for cfDNA in transfusion medicine. These include monitoring antibody-mediated rejection (AMR), assessing hematopoietic activity, detecting microchimerism in patients receiving chronic transfusions, and identifying infections through microbial cfDNA analysis.
“cfDNA is a promising biomarker that is reshaping transfusion medicine. Its proven utility in fetal blood group genotyping and transplant surveillance is expanding to encompass AMR monitoring, hematopoietic activity monitoring, and pathogen detection,” the authors said.
One particularly notable application is the potential to evaluate hematopoiesis without invasive procedures. “cfDNA offers a novel, minimally invasive approach to evaluating hematopoiesis without the requirement of a bone marrow biopsy,” the authors added.
Such approaches could provide laboratories with new tools to assess conditions such as anemia and thrombocytopenia, potentially reducing reliance on bone marrow biopsies in certain clinical scenarios.
Looking ahead, further advances in assay performance and standardization will be essential for broader clinical adoption. “As cfDNA assay technologies advance and tissue-specific markers become better standardized, this approach could enable more personalized monitoring and earlier detection of transfusion-related complications,” Audon said in a press release.
